The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study

Laura Ferraro a,*, Caterina La Cascia a, Daniele La Barbera a, Teresa Sanchez-Gutierrez b, Giada Tripoli a, Fabio Seminerio a, Crocettarachele Sartorio a, Giovanna Marrazzo a, Lucia Sideli a, Celso Arango c, Manuel Arrojo d, Miguel Bernardo a, Julio Bobes e, Cristina Marta Del-Ben f, Charlotte Gayer-Anderson h, Hannah E. Jongsma i, James B. Kirkbridge i, Antonio Lasalvia j, Sarah Tosato k, Pierre-Michel Llorca l, Paolo Rossi Menezes m, Bart P. Rutten n, Jose Luis Santos o, Julio Sanjuán p, Jean-Paul Selten n,q, Andrei Szöke r, Ilaria Tarricone s, Roberto Muratori t, Andrea Tortelli u, Eva Velthorst v,w, Victoria Rodríguez x, Andrea Quattrone y, Peter B. Jones z,ab, Jim Van Os x,ab, Evangelos Vassos ac, Craig Morgan h, Lieuwe de Haan ad, Ulrich Reininghaus bh, Alastair G. Cardno af, Marta Di Forti ac,ag, Robin M. Murray (x,ag), Diego Quattrone (ac,ae,ag)

* Department of Biomedicine, Neuroscience and Advanced Diagnostic (BIND), Section of Psychiatry, University of Palermo, Via G. La Loggia 1, 90129 Palermo, Italy
b Department of Psychology, Universidad Internacional de la Rioja (UNIR), Spain
c Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, HSGM (CIBERSAM), C/Docto Ezquerdo 46, 28007 Madrid, Spain
d Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain
e University Medical Centre, P.O. Box 616, 6200, MD, Maastricht, the Netherlands
f Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Julian Clavería s/n, 33006 Oviedo, Spain
g Department of Preventive Medicine, Faculdade de Medicina FMUSP, University of São Paulo, São Paulo, Brazil
h Department of Health Service and Population Research, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
i Psychiatric Group, Division of Psychiatry, University College London, 6th Floor, Maple House, 149 Tottenham Court Road, London W1T 7NF, UK
j Section of Psychiatry, Azaenda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
k Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy
l Université Clermont Auvergne, EA 7280, Clermont-Ferrand 63000, France
m Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
n Department of Psychiatry and Neupropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, P.O. Box 616, 6200 MD, Maastricht, the Netherlands
o Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz", C/Hermandad de Donantes de Sangre, 16602 Cuenca, Spain
p Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Avda. Blasco Ibáñez 15, 46010 Valencia, Spain
q Rivierdienst Institute for Mental Health Care, Sandfifordegracht 19, 2333 ZZLeiden, the Netherlands
r INSERM, U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France
s Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Popoli 5, 40126 Bologna, Italy
t Department of Mental Health and pathological addictions, Bologna Local Health Authority, Italy
u Établissement Public de Santé Maison Blanche, Paris 75020, France
v Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, Department of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, the Netherlands
w Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA
x Department of Psychiatry Studies, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
y National Health Service, Villa Betania Institute, Reggio Calabria, Italy
z Department of Psychiatry, University of Cambridge, Cambridge, UK

* Corresponding author at: Department of Experimental Biomedicine and Clinical Neurosciences (BIND), Psychiatry Section, University of Palermo, Via G. La Loggia 1, 90129 Palermo, Italy.
E-mail address: laura.ferraro@unipa.it (L. Ferraro).

https://doi.org/10.1016/j.schres.2021.08.008
Received 23 November 2020; Received in revised form 14 July 2021; Accepted 4 August 2021
Available online 14 August 2021
0920-9964/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Premorbid functioning and cognitive measures may reflect gradients of developmental impairment across diagnostic categories in psychosis. In this study, we sought to examine the associations of current cognition and premorbid adjustment with symptom dimensions in a large first episode psychosis (FEP) sample.

We used data from the international EU-GEI study. Bifactor modelling of the Operational Criteria in Studies of Psychotic Illness (OPCRIT) ratings provided general and specific symptom dimension scores. Premorbid Adjustment Scale estimated premorbid social (PSF) and academic adjustment (PAF), and WAIS-brief version measured IQ. A MANCOVA model examined the relationship between symptom dimensions and PSF, PAF, and IQ, having age, sex, country, self-ascribed ethnicity and frequency of cannabis use as confounders.

In 785 patients, better PSF was associated with fewer negative (B = −0.12, 95% C.I. −0.18, −0.06, p < 0.001) and depressive (B = −0.09, 95% C.I. −0.15, −0.03, p = 0.032) symptoms, and more manic (B = 0.07, 95% C.I. 0.14, p = 0.023) symptoms. Patients with a lower IQ presented with slightly more negative and positive, and fewer manic symptoms. Secondary analysis on IQ subdomains revealed associations between better perceptual reasoning and fewer negative (B = −0.09, 95% C.I. −0.17, −0.01, p = 0.023) and more manic (B = −0.10, 95% C.I. 0.10, 0.18, 95% C.I. −0.18, −0.01, p = 0.024).

These findings suggest that the negative and manic symptom dimensions may serve as clinical proxies of different neurodevelopmental predisposition in psychosis.

1. Introduction

Premorbid and cognitive impairment at the first episode of psychosis (FEP) is associated with a worse psychosis outcome (Kravariti et al., 2019; Rabinowitz et al., 2006, 2005; Díaz-Caneda et al., 2015). However, such impairment is not diagnosis-specific (Arango et al., 2014; Cole et al., 2012; Horton et al., 2015; Larsen et al., 2004; Parelada et al., 2017; Sheffield et al., 2018). Although cognitive impairment in bipolar disorder seems to be generally more severe than in psychotic depression and less severe than in schizophrenia, cognitive function may also vary considerably among patients with the same diagnosis (Sheffield et al., 2018; Trotta et al., 2015; Zanelli et al., 2010).

The transdiagnostic and interindividual variability of premorbid and cognitive factors contributes to the well-known impossibility in setting neat boundaries between the categories of schizophrenia, schizoaffective, and bipolar and major depressive disorders with psychotic features (Laursen et al., 2009; Upthegrove et al., 2017).

Given that premorbid functioning and cognitive measures may reflect differential gradients of developmental impairment in psychosis (Demjaha et al., 2012a; Murray et al., 2004; Owen and O’Donovan, 2017), a model based on continuous symptom dimensions (Quattrone et al., 2019; Van Os et al., 1999) would be methodologically appropriate for examining how these features impact psychosis expression (Guerra et al., 2002; Kravariti et al., 2012; Linscott and van Os, 2010).

Previous studies using symptom dimensions have mostly focused on non-affective psychotic disorders. They showed an association between worse premorbid and cognitive factors with more negative and disorganised, but not positive and depressive symptoms (reviewed by de Gracia Domínguez et al., 2009; Ventura et al., 2010). Interestingly, one study including both non-affective and affective dimension at FEP confirmed that negative symptoms were associated with lower IQ and processing speed, while mania showed an inverted-U-shape relationship so that patients with intermediate levels of mania had better cognitive performance than those with low or high levels (Kravariti et al., 2012). Premorbid adjustment in schizophrenia has also been found to be worse in patients with more disorganised (Cohen et al., 2010) and negative symptoms (Bucci et al., 2018b), even when considering FEP samples alone (Chang et al., 2016; Grau et al., 2016; Monte et al., 2008; Stouten et al., 2017); whereas there is mixed evidence on the association between poor premorbid adjustment and positive symptoms (Bril et al., 2009; Bucci et al., 2018b; Chang et al., 2016; Grau et al., 2016; Guerra et al., 2002; MacBeth and Gumley, 2008; Páva et al., 2013; Stouten et al., 2017).

Nevertheless, the paucity of data on premorbid and cognitive features by symptom dimensions in the whole psychosis spectrum (i.e. including both non-affective and affective psychotic disorders) is also caused by the absence of a systematic examination of manic symptoms in the literature (de Gracia Domínguez et al., 2009). Moreover, few studies have been based on large samples of patients at their first episode of psychosis (FEP), which minimise the confounding effect of the course of the disease on cognitive functioning and symptom presentation. In summary, to date, there are no studies that have used the same standardised methodology across multiple countries to evaluate psychopathology at FEP and its relationship with premorbid and cognitive domains.

In the present study, we used a large epidemiological multinational sample to investigate the relationship of both premorbid adjustment and current IQ on the one hand with a bifactor model of psychopathology at FEP on the other. Such a bifactor model comprises 1) a general psychosis factor, which accounts for the variance of all symptoms in the psychosis spectrum; and 2) specific symptom dimensions, that account for the variance due to specific subgroups of symptoms (i.e. positive, negative, disorganisation, manic, and depressive symptoms), independently from the general factor (Reininghaus et al., 2016; Reise et al., 2007). That is, while the general psychosis factor is a measure of the shared symptom presentation in this FEP sample, the specific symptom dimensions instead reflect its heterogeneity.

We expected that premorbid and cognitive measures would account for some heterogeneity in symptom presentation at FEP. Therefore, these measures would explain more variation in specific symptom dimensions than in the general psychosis factor.

More specifically, since the negative symptom dimension can be regarded as a clinical proxy of more neurodevelopmental impairment, we expected that worse premorbid adjustment and cognitive
functioning would be associated with more severe negative symptoms. Moreover, we examined if, as opposed to negative symptoms, the manic symptom dimension would indicate less neurodevelopmental impairment, and therefore associated with a better premorbid adjustment and current cognitive functioning.

2. Methods

2.1. Study design

Subjects were recruited between 01/05/2010 and 01/04/2015 across centres in five different European countries (UK, Italy, Spain, Netherlands, France) and Brazil, as part of The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study (http://www.eu-gei.eu/) (CORDIS, 2019; European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI) et al., 2014; Gayer-Anderson et al., 2020; Jongsmma et al., 2018; van Os et al., 2008) with the overall aim to examine incidence rates and risk factors of psychotic disorders.

2.2. Subjects

Centrally trained researchers screened all potential FEP patients, presenting with a clinical diagnosis for an untreated FEP, even if long-standing, at the mental health services and residents in each catchment area. Since this was a sample of consenting patients derived from an incidence study, inclusion criteria were age 18-64 years and having received operationalised diagnosis of a psychotic disorder (ICD-10: F20-F33) from their clinicians, and confirmed by the researchers, through the Operational Criteria in Studies of Psychotic Illness (OPCRIT) system. Inter-rater reliability was regularly assessed throughout the study. Exclusion criteria were psychotic symptoms precipitated by acute intoxication (ICD10: F1X.5), psychosis due to another medical condition (ICD10: F09) (World Health Organization, 1992), and a previous anti-psychotic medication prescription and/or previous contact with mental health services for psychosis. All local ethical committees approved the study (Gayer-Anderson et al., 2020; Jongsmma et al., 2018).

2.3. Measures

We collected sociodemographic data using the Medical Research Council (MRC) sociodemographic schedule (Mallett et al., 2002). Psychopathology was rated using the OPCRIT system, a 90-item semi-structured interview, of which 59 items concern psychopathology (McGuffin et al., 1991; Williams et al., 1996). The estimation of general and specific symptom dimensions’ scores was described in full in our previous study (Quattrone et al., 2019) and summarised in the supplementary material. Briefly, the general psychosis factor score measured the covariance due to all psychopathology items, with stronger factor loadings from manic and delusional items. In parallel, the specific symptom dimension scores measured the remainder of variance due to subgroups of positive, negative, disorganisation, manic and depressive items.

IQ was assessed by an abbreviation of the Wechsler Adult Intelligence Scale–III (WAIS-III, ref), including four subtests: Digit Symbol Substitution (Processing Speed), Arithmetic (Working Memory), Block Design (Perceptual Reasoning) and Information (Verbal Comprehension) (Vellhorst et al., 2013).

Nine dimensions from the Premorbid Adjustment Scale (PAS) (Cannon-Spooor et al., 1982; Rabinowitz et al., 2007) assessed premorbid social (PSF) and academic (PAF) adjustment in two distinct developmental age-periods: childhood to age 11 and early adolescence (i.e. 12 to age 16) (Rabinowitz et al., 2002; van Mastrigt and Addington, 2002). PSF included social withdrawal (<11 and 12-16 years), peer relationships (<11 and 12-16 years), and ability to form socio-sexual relationships (designed from 12 to age 16 only). PAF included scholastic performance (<11 and 12-16 years), and adaptation to school (<11 and 12-16 years) (Ferraro et al., 2019). IQ calculation and the PAS reduction of dimensions (Ferraro et al., 2019) included in these analyses were described in our previous studies, also summarised in the supplementary material.

Date of onset and weeks of untreated psychosis (DUP) were recorded by the Nottingham Onset Scale (Singh et al., 2005). Thus, for retrospective interviews, we ensured that they referred to the pre-onset period (Gayer-Anderson et al., 2020). A medication list was recorded, including antipsychotic (AP) treatment, codified as AP free/1 AP /more than 1 AP. The Cannabis Experience Questionnaire (CEQ-EU-GEI) evaluated the frequency of cannabis use (Di Forti et al., 2019).

The core assessment (Gayer-Anderson et al., 2020) was administered as soon as the patient was compliant; psychopathology was rated by clinicians referring to any symptoms experienced within the first month of FEP; the WAIS and other retrospective measures (such as PAS) were proposed when the patient mental state was stable, as confirmed by his/her clinicians.

2.4. Statistical analysis

The analysis was performed following two steps in SPSS 25 (IBM Corporation, 2017).

First, we used multivariable analysis of the covariance (MANCOVA) to test the difference in symptom dimensions (the output), based on concomitant discrete and continuous independent variables (age, sex, self-reported ethnicity [white, black, or other ethnicities], study country, PSF, PAF, and IQ scores), so that the relationships found between one dimension and the predictors accounted for (a) for those between the others, (b) and the intra-individual correlation of the dimensions in their severity. Given our previous reports in the EU-GEI study of an association between frequency of lifetime cannabis use with more positive and fewer negative symptoms (Quattrone et al., 2020), as well as better PSF and IQ (Ferraro et al., 2019, 2013), we added this variable as an additional ordinal predictor (i.e. never use = 0; occasional/less than daily use = 1; daily use = 2) (Ferraro et al., 2019). Box’s M test examined the covariance matrix, and effect size estimates were evaluated by Pillai’s trace and partial eta squared.

Second, we aimed to investigate if any specific cognitive function had a stronger relationship with the outcome than others. Thus, exploratory post hoc analyses were run by follow-up ANCOVAs with IQ subtests, PSF, PAF as the independent predictors, and age, sex, self-reported ethnicity, and study country as confounders, and those symptom dimensions where IQ had an effect as the dependent variables (inserted once at a time). Moreover, we were interested to test frequency of cannabis use role in those specific symptom dimensions where it had an effect, and its interactions with premorbid adjustment and current IQ scores if appropriate (i.e., if both terms were predictive per se). All comparisons in MANCOVA and ANCOVAs were Bonferroni-adjusted and further corrected using the Benjamini-Hochberg (B–H) procedure, pre-determining a 5% chance of a false discovery rate.

Following-up the Kravariti et al. (2012) study, we used a post hoc curve estimation regression to explore whether the association between manic symptoms and cognitive performance followed a U-shape (quadratic) better than a linear relationship, based on Akaike and Bayesian Information Criteria (AIC and BIC).

Finally, we wanted to repeat the MANCOVA by including DUP and AP treatment as covariates, to avoid any influence of long-lasting symptomatology and pharmacotherapy on the relationship between the variables of interest.

3. Results

3.1. Descriptive characteristics

785 out of 1130 FEP patients from the original sample (Di Forti et al., 2019).
had a complete set of information for symptom dimensions, IQ, PAF and PSF, and confounding and mediating variables. The subjects included in this sample were not different from the rest of the sample in terms of sex (61.3% males vs. 62.6% males, \( \chi^2(1) = 0.18, p = 0.67 \)) and ethnicity (65.2% white vs. 58.8% white, \( \chi^2(2) = 4.73, p = 0.09 \), but they were younger (Mean 30.5 (sd = 10.3) vs. Mean 33 (sd = 11.1)), t(2,1128) = 3.7, p < 0.001. This sample had a lower proportion of patients from the UK (18.5% vs. 29.3% vs.) and Italy (11.8% vs. 27.2), as compared to the rest of the sample (\( \chi^2(5) = 94.8, p < 0.001 \)).

The mean age of the sample was 30.5 years (sd = 10.3), and the majority of the subjects were male (61.3% [N = 481]), white (65.2% [N = 512]), unemployed (56.7% [N = 445]), single (64.5% [N = 506]), and living with their parents or another family (58.1% [N = 518]) at the time of the interview. 42.7% (N = 335), had a first-level (professional, A-level) education. Supplementary Table 1 mean IQ of the study sample was 85.5 (sd = 18.1), and 66% (N = 518) of the subjects had used cannabis in their lifetime (Table 1). 75.5% (B = 0.005, 95% C.I. -0.01, 0.0, p = 0.333). Negative symptoms were associated with lower IQ, although the magnitude of the association was very small (B = -0.005, 95% C.I. -0.01, -0.001, p = 0.049) and with worse PSF (B = -0.12, 95% C.I. -0.18, -0.06, p < 0.001). By contrast, manic symptoms were slightly more common in patients with higher IQ (B = 0.005, 95% C.I. 0.004, 0.009, p = 0.03), and better PSF (B = 0.07, 95% C.I. 0.14, 0.01, p = 0.023). Depressive symptoms were more common in individuals with lower PSF (B = -0.09, 95% C.I. -0.15, -0.03, p = 0.032). Finally, we did not observe an association between IQ and/or PSF with the general psychosis factor or the disorganisation symptom dimensions (Table 3).

A small effect on the model was observed for cannabis use on symptom dimensions [Pillai’s Trace = 0.019, F(6, 765) = 2.52; p = 0.020; partial \( \eta^2 = 0.019 \)] and premorbid social impairment (PSF) [Pillai’s Trace = 4.26; p < 0.001; partial \( \eta^2 = 0.032 \)] had an overall discriminant effect of a small magnitude on symptom dimensions, whereas academic premorbid impairment (PAF) did not [Pillai’s Trace = 0.007, F(6, 765) = 0.93; p = 0.468; partial \( \eta^2 = 0.007 \)].

### Table 1

| Effect | Pillai’s Trace | F | df | Error df | p-Value | Partial \( \eta^2 \) |
|--------|----------------|---|----|-----------|---------|---------------------|
| Intercept | 0.04 | 5.253 | 6 | 765 | <0.001 | 0.04 |
| Country | 0.321 | 8.3 | 30 | 3845 | <0.001 | 0.064 |
| Gender | 0.019 | 2.49 | 6 | 765 | 0.022 | 0.019 |
| Ethnicity | 0.029 | 1.872 | 12 | 1532 | 0.034 | 0.014 |
| Age | 0.051 | 6.912 | 6 | 765 | <0.001 | 0.051 |
| PSF | 0.032 | 4.266 | 6 | 765 | <0.001 | 0.032 |
| PAF | 0.007 | 0.937 | 6 | 765 | 0.468 | 0.007 |
| IQ | 0.019 | 2.527 | 6 | 765 | 0.02 | 0.019 |
| Frequency of cannabis use | 0.027 | 1.763 | 12 | 1532 | 0.049 | 0.014 |

* Design: Intercept + country + gender + ethnicity + age + PSF + PAF + IQ + frequency of cannabis use.

(Table 2). Positive symptoms were slightly more common in individuals with lower IQ (B = -0.005, 95% C.I. -0.01, 0.0, p = 0.333). Negative symptoms were associated with lower IQ, although the magnitude of the association was very small (B = -0.005, 95% C.I. -0.01, -0.001, p = 0.049) and with worse PSF (B = -0.12, 95% C.I. -0.18, -0.06, p < 0.001). By contrast, manic symptoms were slightly more common in patients with higher IQ (B = 0.005, 95% C.I. 0.004, 0.009, p = 0.03), and better PSF (B = 0.07, 95% C.I. 0.14, 0.01, p = 0.023). Depressive symptoms were more common in individuals with lower PSF (B = -0.09, 95% C.I. -0.15, -0.03, p = 0.032). Finally, we did not observe an association between IQ and/or PSF with the general psychosis factor or the disorganisation symptom dimensions (Table 3).

A small effect on the model was observed for cannabis use on symptom dimensions [Pillai’s Trace = 0.027, F(12, 1532) = 1.76; p = 0.049; partial \( \eta^2 = 0.014 \) (Table 1)]. Specifically, positive symptoms were higher in individuals with daily use of cannabis, compared with never (B = -0.270, 95% C.I. -0.478, -0.061, p = 0.011) and occasional users (B = -0.256, 95% C.I. -0.442, -0.07, p = 0.007). Other variables’ effects are described in the supplementary material.

### 3.2. Predictive model for symptom dimensions by premorbid adjustment and cognition

The MANCOVA analysis showed that IQ [Pillai’s Trace = 4.26; p < 0.001] and premorbid social impairment (PSF) [Pillai’s Trace = 4.26; p < 0.001] had an overall discriminant effect of a small magnitude on symptom dimensions, whereas academic premorbid impairment (PAF) did not [Pillai’s Trace = 0.007, F(6, 765) = 0.93; p = 0.468; partial \( \eta^2 = 0.007 \)].

### Table 2

Multivariate tests discriminate effects.

- Intercept: adding effect of IQ on symptom dimensions.
- Country: adding effect of country on symptom dimensions.
- Gender: adding effect of gender on symptom dimensions.
- Ethnicity: adding effect of ethnicity on symptom dimensions.
- Age: adding effect of age on symptom dimensions.
- PSF: adding effect of PSF on symptom dimensions.
- PAF: adding effect of PAF on symptom dimensions.
- IQ: adding effect of IQ on symptom dimensions.
- Frequency of cannabis use: adding effect of frequency of cannabis use on symptom dimensions.

We then examined the effect of processing speed, working memory, perceptual reasoning, and verbal comprehension on negative, manic and positive dimensions, with the additional confounder effect of frequency of cannabis use on the positive symptom dimension only.

Associations of small magnitude were observed for perceptual reasoning with a lower score on the negative symptom dimension (B = -0.17, 95% C.I. -0.1, -0.1, p = 0.001) and with worse PSF (B = 0.10, 95% C.I. 0.02, 0.18, p = 0.014). In a post hoc analysis, we found that the quadratic term (AIC = 2266.346; BIC = 2317.972) did not improve the model compared with the linear one (AIC = 2265.142; BIC = 2316.768). Thus, we maintained the assumption of a linear relationship between manic symptoms and perceptual reasoning.

Associations of small magnitude were also observed for worse processing speed (B = -0.12, 95% C.I. -0.02, 0.004, p = 0.003) and
working memory (B = −0.10, 95% CI. −0.18, −0.01, p = 0.024) and a higher score on the positive symptom dimension.

Higher frequency of cannabis use was moderately associated with higher positive symptom scores (never vs daily use B = 0.25, 95% CI 0.04, 0.46, p = 0.016; occasional vs daily use B = 0.24, 95% CI 0.05, 0.42, p = 0.010).

We found evidence for a positive symptom-by-cannabis use interaction effect, suggesting that processing speed is differently associated with positive symptoms, depending on frequency of cannabis-use (F(2, 767) = 3.1, p = 0.047, partial η² = 0.008). Specifically, cannabis daily-users had more positive symptoms than never- (B = 0.273, 95% CI. 0.02, 0.52, p = 0.030) and occasional users (B = 0.245, 95% CI. 0.019, 0.47, p = 0.029), regardless of their processing speed scores. However, within the group of occasional cannabis users, positive symptoms were fewer when processing speed deficits were less pronounced (B = −0.22, 95% CI. −0.4, −0.03, p = 0.017, partial η² = 0.007) (Supplementary-Fig. 1).

4. Discussion

First, we found that premorbid social functioning was independently associated with specific patterns of symptom presentation. FEP patients with lower levels of social adjustment presented with more negative and depressive symptoms, whereas those with higher levels of social adjustment presented with more manic symptoms.

Second, we found an independent, small association between IQ and symptom dimensions. Specifically, patients with current lower IQ presented with slightly more negative and positive symptoms and fewer manic symptoms compared with those with higher IQ scores. However, these associations were of small magnitude.

Third, when considering IQ sub-tests, we found that specific cognitive sub-domains drove the association between IQ and symptom presentation. That is, while lower processing speed and working memory were associated with more positive symptoms, lower perceptual reasoning was associated with more negative and fewer manic symptoms.

4.1. Manic and negative symptoms

Our findings are congruent with previous studies focused on individuals at risk for psychosis (Tarbox et al., 2013) and around the onset of first psychosis. (Paya et al., 2013; Chang et al., 2013; Horton et al., 2015), suggesting that variation in cognitive and premorbid social features is associated with different early trajectories of premorbid adjustment.

In our study, higher IQ and better premorbid sociability were associated with more manic symptoms and fewer negative symptoms, which is in line with the suggested heterogeneity in neurodevelopmental predisposition in psychosis. Indeed, negative symptoms at FEP are often considered a marker of early developmental impairment (Murray and Castle, 1991).

When considering diagnoses, more severe neurodevelopmental impairment has been extensively reported in schizophrenia than in bipolar disorders (Allardyce et al., 2007; Bucci et al., 2018a; Koenen et al., 2009; Mollon et al., 2018; Torrent et al., 2018; Trotta et al., 2015). Altogether, these elements support the hypothesis of a continuous distribution of neurodevelopmental impairment across the psychosis spectrum and within disorders; to some extent, the categories of...
schizophrenia and bipolar disorder might approximately catch the high and low extremes of this distribution (Arango et al., 2014; Demjaha et al., 2012b; Murray et al., 2004; Parellada et al., 2017).

The association between IQ and negative and manic dimensions was largely driven by the perceptual-reasoning domain, which is related to perceptual abnormalities (Morita et al., 2019; Silverstein and Keane, 2011) and to the speed of thinking process (Scheiber et al., 2017), which is accelerated in manic episodes and decelerated in negative states. Perceptual-reasoning is also considered a proxy of ‘general ability index’ of intelligence, able to overcome subjects’ linguistic problems (Green et al., 2008), and it is generally more impaired in schizophrenia compared with other psychotic disorders.

We reported this association using a delimited negative symptom dimension composed of restrictive and blunted affect and poverty of speech.

These findings are in line with one previous report on FEP patients concerning negative and manic symptoms (Kravariti et al., 2012). However, unlike Kravariti et al. (2012), we did not find an inverse U-shape relationship between cognition and manic symptoms. Of note, we choose to do not exclude patients with IQ < 70; this contributed to lower the median IQ of the sample, but it made our findings reflecting the real clinical practice.

4.2. Positive symptoms

Positive symptoms were associated with lower current IQ but not with worse premorbid adjustment. This relationship was driven by lower processing speed and worse working memory, which are well-recognised early neuropsychological markers of schizophrenia (Dickinson et al., 2007; Forbes et al., 2009; Lee and Park, 2005; Silver et al., 2003). On the other hand, a deficit in working memory has been reported both in individuals with schizophrenia and bipolar disorder currently experiencing auditory verbal hallucinations (Jenkins et al., 2018) that may be linked to dysfunctions in verbal memory encoding (Gisselgård et al., 2014).

Processing speed may relate to a broad range of cognitive dysfunctions, more than merely low-speed (Ayessa-Arriola et al., 2016; Rodríguez-Sánchez et al., 2007), and it implies encoding abilities as well (Mathias et al., 2017).

Indeed, these cognitive sub-domains are probably associated to fluid intelligence (Fry and Hale, 2000; Neisser et al., 1996; Yuan et al., 2006), and their functioning increases in concert as the effect of the cognitive-developmental cascade (Fry and Hale, 2000). Thus, their dysfunction might precede or be contextual to the diagnosis and can contribute to the aberrant coding typical of positive symptoms (Freeman et al., 2014; Laloyaux et al., 2018; Zhu et al., 2018). Given the result of our supplementary analysis, including the effect of AP medication, it is unlikely that these results are related to the use of antipsychotics at the time of the interview.

Of note, fluid intelligence is not only state-, but also and trait-dependent. Hence, we cannot firmly establish a causal direction of this association between positive symptoms and lower processing speed and general IQ. However, more insight on it can derive from the interactive effects of patterns of cannabis use.

The frequency of cannabis use was associated with more prominent positive symptoms at FEP (Ringen et al., 2016; Seddon et al., 2016), in a dose-response effect (Quattrone et al., 2020). Particularly, we found an interaction between cannabis use and processing speed in predicting positive symptoms in the group of occasional cannabis users. Such a group of patients may present with the most cognitively-related positive symptoms, i.e. being not related to neurodevelopmental impairment, compared with never users (Ferraro et al., 2019), as well as to long-lasting or residual effects of cannabis use, compared with daily users (Quattrone et al., 2020) (see supplementary material). Therefore, it is intriguing to speculate whether cannabis use could be considered as a transdiagnostic proxy of less neurodevelopmental impairment in psychotic disorders. Notably, never users presented with the lowest positive symptoms, regardless of their processing speed abilities, in line with the finding of a predominance of negative symptoms in this subgroup (Pope et al., 2021; Quattrone et al., 2020).

4.3. Depressive symptoms

Worse premorbid sociability but not current cognition was associated with depressive symptoms, in line with previous studies (Tarbox et al., 2012). These findings support a difference between mood down-regulation and flat affect, the second being more a cognitively-related deficit in the emotion-processing, while depressive symptom dimension in psychosis could be part of a motivational impairment, independent from negative symptoms (Culbrett et al., 2018), which needs further attention from both a research and clinical point of view (Upthegrove et al., 2017).

4.4. Disorganised symptoms

Disorganisation is often indicative of a lower psychosocial functioning (Minor et al., 2015; Minor and Lysaker, 2014); however, in our sample, we did not find any relationship of current cognitive characteristics and premorbid adjustment with disorganisation symptoms at FEP. Consistent with previous literature (Díaz-Caneja et al., 2015; Drake et al., 2016; Gaderis et al., 2012; Morgan et al., 2008; Petruzzelli et al., 2018), men in our sample showed more disorganised and negative symptoms than women; furthermore, an earlier age-of-onset was related to more disorganised and negative and fewer depressive symptoms, in line with hypothesised sex-related neurodevelopmental characteristics of psychosis (Murray and Castle, 1991; Riecher-Rössler and Häfner, 2000; Seeman, 1997).

4.5. General psychosis factor

Finally, we found that the general psychosis factor was not associated with cognitive and premorbid features. This firstly suggests that current cognitive characteristics and premorbid adjustment at FEP may reflect specific symptom-developmental predisposition as opposed to unspecific, common psychopathology. Moreover, this finding should be put in the context of the general factor conceptualisation in the EU-GEI FEP sample (Quattrone et al., 2019), where the identified general psychosis factor catch the shared characteristics across diagnostic categories of non-affective and affective psychosis (Quattrone et al., 2019). Of note, the conceptualisation of a general factor in our sample, and its relationship with cognitive and premorbid features, may be different from samples that include all psychiatric diagnoses (Kotow et al., 2020), or the general population (Casp et al., 2020; Murphy et al., 2020). In such scenarios, the general factor reflects a wider range of symptoms than psychosis, and it may therefore serve as a more general index of psychopathology.

5. Limitations

This study has two main limitations. First, we used a narrow negative symptom dimension due to the limited coverage of negative symptoms of the OPCRIT (Quattrone et al., 2019). Still, our findings are in line with previous literature, and they are, overall, coherent with a developmental risk model of psychosis (Murray et al., 2017). Second, we cannot exclude some extent of recall bias in referring to premorbid adjustment using the PAS. However, the PAS is the most validated tool for measuring premorbid adjustment in patients who have been diagnosed with a psychotic disorder (Brill et al., 2008; Rabkinowitz et al., 2007). Finally, our PAS measures stop at age 16 (early adolescence), to prevent overlap with illness onset, while previous studies reported the most significant deterioration between 16 and 18 years (late adolescence) for the academic factor (PAF) (Allen et al., 2013; Strauss et al., 2012). This could be
responsible for the counterintuitive finding of a lack of association between a worse PAF and symptomatological markers of neurodevelopmental impairment, such as negative or depressive symptoms. On the other hand, one of these studies (Strauss et al., 2012) reported a greater premorbid PAF impairment in those with less PSF deficiency, thus suggesting a non-linear association between these two factors. Third, this is a multinational study and, as expected, we observed differences in symptom dimension scores across countries. We consider these differences as reflecting the genuine variation of psychopathology in different contexts. Indeed, all researchers underwent a psychopathology OPCRIT rating and inter-rater reliability was calculated before and during the study. Moreover, country, used as a confounder, did not affect our main findings, which are in turn more generalizable due to the multinational design of the EU-GEI study.

6. Conclusions

Our findings support the use of symptom dimensions in psychosis research and clinical practice. Indeed, the plausibility of such continuous phenotypes depends on both their validity and the degree of useful information that can be derived by their examination.

From a research perspective, we evaluated a dimensional symptom-developmental model of psychosis. In our sample, cognitive abilities and premorbid functioning contributed to the heterogeneous expression of psychosis at FEP. Assuming that dysfunction in current cognitive and premorbid social abilities are indicative of more neurodevelopmental impairment in psychosis, we may speculate that our findings reflect the existence of different neurodevelopmental predispositions in psychosis, resulting in differential symptomatology at FEP.

From a clinical perspective, the identification of premorbid and cognitive features associated with symptom presentation may be relevant to overcome certain issues with psychiatric nosology. In addition to the traditional diagnoses, mental health professionals should be encouraged to formulate enhanced clinical impressions, integrating their evaluation of symptoms at FEP with information on personal history and cognitive functioning. Our findings suggest that premorbid academic poor adjustment could be a less sensitive risk-factor than an early social poor adjustment, which would require further attention and consideration in future studies, where the use of both these measured would be highly recommended.

CRediT authorship contribution statement

Authors LF and DQ designed the study and wrote the protocol, they made statistical analyses and wrote the first draft of the manuscript. Authors CLC, TSG, GT, FS, CS, GM and LS helped with the literature searches and the revision of the manuscript.

Authors DLB, CA, MB, EV, PBJ, CM, HEJ, JBK, ST, PML, JPS, IT, RM, JVO, EV, LDH, AGC, MDF provided valuable feedback on previous versions and approved the final manuscript. RMM provided his valuable feedback, supervised on previous versions and approved the final manuscript.

Role of the funding source

The funding sources had no involvement in the conduct of the research and preparation of the article, in study design, in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Declaration of competing interest

The authors have no conflicts of interest to declare in relation to the work presented in this paper.

Acknowledgements

The EU-GEI Study is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme, and Grant 2012/0417-0 from the São Paulo Research Foundation. DQ’s research was supported by a Guarantors of Brain post-doctoral clinical fellowship. The work was further funded by: Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF.

The European Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI) WP2 Group non-author members include: (Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK), Stephanie Beards (Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK), Simona A. Stilo (Department of Psychiatry Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK), Maria Parelada (Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Investigación Sanitaria del Hospital Gregorio Marañón (IISGM), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain), Pedro Cuadrado (Villa de Vallecas Mental Health Department, Villa de Vallecas Mental Health Centre, Hospital Universitario Infantia Leonor/Hospital Virgen de la Torre, Madrid, Spain), José Juan Rodríguez Solano (Puente de Vallecas Mental Health Department, Hospital Universitario Infanta Leonor/Hospital Virgen de la Torre, Centro de Salud Mental Puente de Vallecas, C/Peña Gorbea 4, 28018 Madrid, Spain), Angel Carracedo (Fundación Pública Galega de Medicina Xenoméxico, Hospital Clínico Universitario, Choupana s/n, 15782 Santiago de Compostela, Spain), David Fraguas MD, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, IISGM, School of Medicine, Universidad Complutense, Madrid, Spain), Álvaro Andreu-Bernabeu MD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, IISGM, School of Medicine, Universidad Complutense, Madrid, Spain), Gonzalo López (Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Investigación Sanitaria del Hospital Gregorio Marañón (IISGM), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain), Bibiana Cabrera (Department of Psychiatry, Hospital Clinic, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Universidad de Barcelona, C/Villarroel 170, escalera 9, planta 6, 08036 Barcelona, Spain), Esther Lorente-Rovira (Department of Psychiatry, School of Medicine, Universidad de València, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Avda. Blasco Ibáñez 15, 46010 Valencia, Spain), Paz García-Portilla (Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Juliana Clavería s/n, 33006 Oviedo, Spain), Javier Costas (Fundación Pública Galega de Medicina Xenoméxico, Hospital Clínico Universitario, Choupana s/n, 15782 Santiago de Compostela, Spain), Estela Jiménez-López (Department of Psychiatry, Servicio de Psiquiatría Hospital Virgen de la Luz, C/ San Juan de Donantes de Sangre, 16002 Cuenca, Spain), Mario Matteis (Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Investigación Sanitaria del Hospital Gregorio Marañón (IISGM), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain), Marta Rapado-Castro (Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Investigaci.n Sanitaria
Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.schres.2021.08.008.

References

Allardycy, J., McCredie, R., Morrison, G., van Os, J., 2007. Do symptom dimensions or categorical diagnoses best discriminate between known risk factors for psychosis? Soc. Psychiatry Psychiatr. Epidemiol. 42, 429–437.

Allen, D.N., Strauss, G.P., Burchard, K.A., Vertinski, M., Carpenter, W.T., Buchanan, R.W., 2013. Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia. Schizophr. Res. 146, 132–137.

Arango, C., Pragnas, D., Parellada, M., 2014. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. Schizophr. Bull. 40, S138–S146.

Ayasa-Ariólda, R., Setién-Suero, E., Neergaard, K.D., Ferro, A., Fajjó-Vilas, M., Ríos-Lago, M., Otero, S., Rodríguez-Sánchez, J.M., Crespo-Facorro, B., 2016. Evidence for trait related theory of mind impairment in first episode psychosis patients and its

del Hospital Gregorio Mara...n (IISGM), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain), Emiliano González (Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Investigación Sanitaria del Hospital Gregorio Marañón (IISGM), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain), Covadonga M. Díaz-Caneja (MD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain), Emilio Sánchez (Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Investigación Sanitaria del Hospital Gregorio Marañón (IISGM), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Doctor Esquerdo 46, 28007 Madrid, Spain), Manuela Durán-Cutilia (MD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, IISGM, School of Medicine, Universidad Complutense, Madrid, Spain), Nathalie Franke (Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands), Fabian Tormeshuizen (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands, Rivierduinen Centre for Mental Health, Leiden, Sandifordtred 19, 2333 ZZ Leiden, The Netherlands), Daniela van der Ven (Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands), Elsje van der Ven (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands, Rivierduinen Centre for Mental Health, Leiden, Sandifordtred 19, 2333 ZZ Leiden, The Netherlands), Elsje van der Ven (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands, Rivierduinen Centre for Mental Health, Leiden, Sandifordtred 19, 2333 ZZ Leiden, The Netherlands), Marion Leboyer (AP-HP, Groupe Hospitalier “Mondor”, Pôle de Psychiatrie, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France, Institut National de la Santé et de la Recherche Médicale (INSERM), U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France, BP 69, 63003 Clermont Ferrand, Cedex 1, France, Université Clermont Auvergne, EA 7280, Clermont-Ferrand 63000, France), Anne-Marie Tronce (Fondation Fondamental, 40 Rue de Mesly, 94000 Créteil, France, CMP B CHU, BP 69, 63003 Clermont Ferrand, Cedex 1, France, Université Clermont Auvergne, EA 7280, Clermont-Ferrand 63000, France), Flora Frijda (Etablissement Public de Santé (EPS), Maison Blanche, París 75020, France), Marcelino Loureiro (Departamento de Neurociencias y Ciencias del Comportamiento, Facultad de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900-Monte Alegre-CEP 14049-900, Ribeirão Preto, SP, Brasil, Núcleo de Pesquisa en Saúde Mental Populacional, Universidade de São Paulo, Avenida Doutor Arnaldo 455, CEP 01246-903, SP, Brasil), Rosana Shuhama (Departamento de Neurociencias y Ciencias del Comportamiento, Facultad de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900-Monte Alegre-CEP 14049-900, Ribeirão Preto, SP, Brasil, Núcleo de Pesquisa en Saúde Mental Populacional, Universidade de São Paulo, Avenida Doutor Arnaldo 455, CEP 01246-903, SP, Brasil), Mirella Ruggieri (Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy), Chiara Bonetto (Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy), Dorian Cristofalo (Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy). Domenico Berardi (Department of Biomedical and NeuroMotor Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy), Marco Seri (Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy), Elena Bonora (PhD, Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy), Giuseppe D’Andrea (MD, Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy), Silvia Amoretti (PhD Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain, CIBERSAM, Spain), Gisela Mezquida (PhD, Centre for Biomedical Research in the Mental Health and Surgical Science of Barcelona, Barcelona, Spain), Chiara Bonetto (Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy). Domenico Berardi (Department of Biomedical and NeuroMotor Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy), Marco Seri (Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy), Giuseppe D’Andrea (MD, Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy), Silvia Amoretti (PhD Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain).
Di Forti, M., Quattrone, D., Freeman, T.P., Tripoli, G., Gayer-Anderson, C., Quigley, H., Demjaha, A., MacCabe, J.H., Murray, R.M., 2012a. How genes and environmental factors contribute to the development of schizophrenia. Schizophr. Res. 136, 1–6. 10.1016/j.schres.2011.10.017.

Di Forti, M., Capone, C., Criocci, G., Rodriguez-Campo, M., Rabinowitz, J., 2008. Validity of the premorbid adjustment scale. Schizophr. Bull. 34, 981–983. 10.1093/schbul/sbn065.

Di Forti, M., Ripolles, T., Lencois, T., Selten, J.P., Decina, A., Storch, E.A., Tonon, S., Marques, A., Elkasrawy, H., Murray, R.M., 2015. Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophr. 1, 1–15. 10.1038/npjscz.2014.5.

Dickinson, D., Ramsey, M.E., Gold, J.M., 2007. Overlooking the obvious: a meta-analytic comparison of digit symbol and other cognitive measures in schizophrenia. Arch. Gen. Psychiatry 64, 532–542. 10.1001/archpsyc.64.7.532.

Díaz-Caneja, M.C., Pinna-Canals, S., Rodríguez-Quiroga, G., Alegre, A., Arango, C., Cyatarovitch, T., Yildirim, M., Lencinas, M., Jardal, S., Arango, C., 2016. How age and gender predict illness course in a first-episode nonaffective psychosis cohort. J. Clin. Psychiatry 77, e283–e289. 10.4088/JCP.14m09369.

European Network of National Studies in Genotyping Environment Interactions in Schizophrenia (EU-GEI) _ Report 7. 2016. https://doi.org/10.1001/jamanetworkopen.2020.3224.

European Network of National Studies in Genotyping Environment Interactions in Schizophrenia (EU-GEI) _ Report 8. 2017. https://doi.org/10.1017/S0033291717002525.

Ferraro, L., Ruscio, M., Di Lorenzo, G., Ribolsi, M., Corrivetti, G., Bartoli, L., Del Buono, G., Girardi, N., Frascarelli, M., Del Casale, A., Comparelli, A., Corigliano, V., Ossola, P., Gerra, M.L., Carmassi, C., Cremone, I.M., Carpita, B., Buzzanca, A., Gattoni, E., Gambaro, E., Tenconi, E., Ferronato, L., Collantoni, E., Tonna, M., Seri, M., Marcacci, T., Chiari, L., Chierici, F., Storni, V., Braca, M., Minenna, M.G., Donegani, I., Fioritti, A., La Barba, D., La Cascia, C., Bale, M., Sidei, L., Santoro, R., Ferraro, L., Tripoli, G., Seminerio, F., Marino, A.M., McGorry, P., Nelson, B., Amminger, G., P.D., Del, M., Bazin, F., Feracchio, A., Richet, J.-R., Bülzack, E., Charpeau, T., Tronche, A.-M., De Het, M., Van Winkel, R., Decoster, J., Decour, C., Thiery, E., Stefanis, N.C., Sachs, G., Aschauer, H., Lasser, I., Winklhaub, B., Schögelmöller, M., Riecher-Rössler, A., Borgwardt, S., Walter, I., Schizophrenia. Schizophr. Bull. 8, 470–484. 10.1093/schbul/sbu100.

Connor, J.H., Kresin, G., Wyatt, R.J., 1982. Measurement of premorbid adjustment in children. Schizophr. Res. 2, 51–60. 10.1016/0920-9964(82)90073-7.

Caspí, A., Batty, G.D., Marmot, M.G., 2005. Life-course socioeconomic status and health: the role of smoking and body mass index in early life. J. Epidemiol. Community Health 59, 691–698. 10.1136/jech.2004.025347.

Caspí, A., Sugden, K., Moffitt, T.E., Taylor, A., Craig, I.W., Harrington, R., McGuffin, P., Mill, J., 2002. Influence of childhood adversity on depression: validation and extension of a developmentaliad model using genetic epidemiology. Arch. Gen. Psychiatry 59, 1188–1196. 10.1001/archpsyc.59.12.1188.

Caspí, A., Batty, G.D., Marmot, M.G., 2006. Life-course socioeconomic status and health: the role of smoking and body mass index in early life. J. Epidemiol. Community Health 59, 691–698. 10.1136/jech.2004.025347.

Caspí, A., Batty, G.D., Marmot, M.G., 2006. Life-course socioeconomic status and health: the role of smoking and body mass index in early life. J. Epidemiol. Community Health 59, 691–698. 10.1136/jech.2004.025347.

Caspí, A., Sugden, K., Moffitt, T.E., Taylor, A., Craig, I.W., Harrington, R., McGuffin, P., Mill, J., 2002. Influence of childhood adversity on depression: validation and extension of a developmentaliad model using genetic epidemiology. Arch. Gen. Psychiatry 59, 1188–1196. 10.1001/archpsyc.59.12.1188.

Caspí, A., Sugden, K., Moffitt, T.E., Taylor, A., Craig, I.W., Harrington, R., McGuffin, P., Mill, J., 2002. Influence of childhood adversity on depression: validation and extension of a developmentaliad model using genetic epidemiology. Arch. Gen. Psychiatry 59, 1188–1196. 10.1001/archpsyc.59.12.1188.

Caspí, A., Sugden, K., Moffitt, T.E., Taylor, A., Craig, I.W., Harrington, R., McGuffin, P., Mill, J., 2002. Influence of childhood adversity on depression: validation and extension of a developmentaliad model using genetic epidemiology. Arch. Gen. Psychiatry 59, 1188–1196. 10.1001/archpsyc.59.12.1188.
Kotov, R., Jonas, K.G., Carpenter, W.T., Dretsch, M.N., Eaton, N.R., Forbes, M.K., Jongsma, H.E., Gayer-Anderson, C., Lasalvia, A., Quattrone, D., Jenkins, L.M., Bodapati, A.S., Sharma, R.P., Rosen, C., 2018. Working memory predicts symptom development and quality of life in first episode psychosis: a systematic review and critical reappraisal. Acta Psychiatr. Scand. https://doi.org/10.1111/1600-0447.12113.

Lau, J., Lee, S., P., 2005. Working memory impairments in schizophrenia: a meta-analysis. J. Abnorm. Psychol. https://doi.org/10.1037/0021-843X.114.4.599.

Linscott, R.J., van Os, J., 2010. Systematic reviews of categorical versus continuous models in psychotic models in psychotic models: evidence for discontinuous subpopulations underlying a psychometric continuum. Implications for DSM-V, DSM-VI, and DSM-VII. Ann. Rev. Clin. Psychol. 6, 391–419. https://doi.org/10.1146/annurev-clinpsy.032008.103506.

Macbeth, A., Gumley, A., 2008. Premorbid adjustment, symptom development and quality of life in first episode psychosis: a systematic review and critical reappraisal. Acta Psychiatr. Scand. https://doi.org/10.1111/1600-0447.12113.

Mallett, R., Leff, J., Bhugra, D., Pang, D., Zhao, J.H., 2002. Social environment, ethnicity and schizophrenia: a case-control study. Soc. Psychiatry Psychiatr. Epidemiol. 37, 329–335.

van Mastrigt, S., Additiong, J., 2002. Assessment of premorbid function in first episode schizophrenia: modifications to the premorbid adjustment scale. J. Psychiatry Neurosci. 27, 92–101.

Mathias, S.R., Knowles, E.E.M., Barrett, J., Leach, O., Buccheri, S., Beetham, T., Blangero, J., Poldrack, R.A., Glahn, D.C., 2017. The processing-speed impairment in psychosis is more than just accelerating aged. Schizophr. Bull. 43, sbw168 https://doi.org/10.1093/schbul/sbw168.

Minor, K.S., Lysaker, P.H., 2014. Necessary, but not sufficient: links between neurocognition, social cognition, and metacognition in schizophrenia are moderated by disorganized symptoms. Schizophr. Res. 159, 198–204. https://doi.org/10.1016/j.schres.2014.05.012.

Minor, K.S., Marggraf, M.P., Davis, B.J., Luther, L., Voils, J.J., Buck, K.D., Lysaker, P.H., 2015. Conceptual disorganization weakens links in cognitive pathways: disentangling neurocognition, social cognition, and metacognition in schizophrenia. Schizophr. Res. 169, 153–158. https://doi.org/10.1016/j.schres.2015.09.026.

Mollon, J., David, A.S., Zammit, S., Lewis, G., Reichenberg, A., 2018. Course of cognitive development from infancy to early adulthood in the psychosis spectrum. JAMA Psychiatry 75, 270–279. https://doi.org/10.1001/jamapsychiatry.2017.4327.

Mor, R.C., Goldberg, R.M., Compton, M.T., 2008. Premorbid functioning of patients with first-episode nonaffective psychosis: a comparison of deterioration in academic, social performance, and clinical correlates of premorbid adjustment scale scores. Schizophr. Res. 104, 206–213.

Morgan, V.A., Castle, D.J., Jablensky, A.V., 2008. Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of low prevalence (Psychotic) disorders. Aust. N. Z. J. Psychiatry 42, 74–82. https://doi.org/10.1080/00048670701732699.

Morita, K., Miura, K., Fujimoto, M., Yamamori, H., Yasuda, Y., Kudo, N., Azechi, H., Okada, N., Koshiyama, D., Ikeda, M., Kasi, K., Hashimoto, R., 2019. Eye movement abnormalities and their association with cognitive impairments in schizophrenia. J. Psychiatr. Res. 110. https://doi.org/10.1016/j.jpsychires.2019.03.022.

Murphy, D., Vallières, F., Murphy, J., McBryde, E., Hyland, P., 2020. Risk factors associated with general and specific dimensions of psychosis in a nationally representative sample of adults from the United States. Psychiatry. Psychol. https://doi.org/10.1017/psyp.2020.143.

Murray, R.M., Castle, D.J., 1991. The neurodevelopmental basis for sex differences in schizophrenia. Psychol. Med. https://doi.org/10.1017/S0033291700022194.

Murray, R.M., Sham, P., Van Os, J., Zanelli, J., Cannon, M., McDonald, C., 2004. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr. Res. 71, 405–416. https://doi.org/10.1016/j.schres.2004.03.002.

Murray, R.M., Bhavsar, V., Tripoli, G., Howes, O., 2017. 30 years on: how the neurodevelopmental hypothesis of schizophrenia evolved into the developmental risk factor model of psychosis. Schizophr. Bull. 43, 1190–1196. https://doi.org/10.1093/schbul/sbx121.

Neisser, U., Boodoo, G., Bouchard, T.J., Boykin, A.W., Brody, N., Cei, S.J., Halpern, D.F., Loehlin, J.C., Perloff, R., Urbina, S., 1996. Intelligence: knowns and unknowns. Am. Psychol. 51, 77–101. https://doi.org/10.1037/0003-066X.51.2.77.

Van Os, J., Rutten, B.P., Poulin, R., 2008. Gene–environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr. Bull. 34, 1066–1082.

Owen, M.J., O’Donovan, M.C., 2017. Schizophrenia and the neurodevelopmental continuum: evidence from genomics. World Psychiatry 16, 227–235. https://doi.org/10.1002/wps.20447.

Parellada, M., Gomez-Valejo, S., Burdeus, M., Arango, C., 2017. Developmental differences between schizophrenia and bipolar disorder. Schizophr. Bull. 43, 1176–1189. https://doi.org/10.1093/schbul/sbx126.

Pays, Y., Rodríguez-Sánchez, J.M., Otero, S., Castro-Fornieles, J., Parellada, M., Gonzalez-Cervantes, M., Arango, C., 2018. Microstructural changes in first-episode psychosis: findings from the eVOS-10 study. Psychol. Med. 49, 2100–2110. https://doi.org/10.1017/S0033291718002957.

Rascher, W., Della Libera, I., 2018. Source flexibility in schizophrenia: specificity and role in auditory hallucinations. Cogn. Neuropsychiatry 23, 393–407.

Rascher, W., Della Libera, I., 2018. Source flexibility in schizophrenia: specificity and role in auditory hallucinations. Cogn. Neuropsychiatry 23, 393–407.
